Clinical Trial Update: Radio-chemotherapy With or Without Panitumumab (Vectibix®) in Irresectable Squamous Cell Carcinoma or Adenocarcinoma of the Oesophagus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating radiochemotherapy with or without panitumumab for irresectable esophageal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Panitumumab (panitumumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Irresectable Squamous Cell or Adenocarcinoma of the Oesophagus | Phase 2 | Status: TERMINATED